A5023957008- Heart Failure Treatment and Management
- Cardiac Imaging and Diagnostics
- Acute Myocardial Infarction Research
- Pericarditis and Cardiac Tamponade
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Function and Risk Factors
- Cardiac Fibrosis and Remodeling
- Viral Infections and Immunology Research
- Cardiac Arrhythmias and Treatments
- Cardiac Structural Anomalies and Repair
- Cardiac Valve Diseases and Treatments
- Cardiovascular Effects of Exercise
- Cardiac Health and Mental Health
- Inflammasome and immune disorders
- Cardiovascular and exercise physiology
- Cardiac electrophysiology and arrhythmias
- Takotsubo Cardiomyopathy and Associated Phenomena
- Cardiac Arrest and Resuscitation
- Coronary Interventions and Diagnostics
- Nutrition and Health in Aging
- Cardiovascular Disease and Adiposity
- Cardiac tumors and thrombi
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac pacing and defibrillation studies
- Trauma and Emergency Care Studies
University of Virginia
2023-2025
Virginia Commonwealth University
2023-2025
University of Insubria
2020-2024
University of Miami Health System
2024
Children's Hospital of Richmond at VCU
2023
Ospedale di Circolo e Fondazione Macchi
2021-2022
Università Cattolica del Sacro Cuore
2017-2022
Aziende Socio Sanitarie Territoriale dei Sette Laghi
2021
NanoQuébec (Canada)
2020
Detroit R&D (United States)
2020
Cannabidiol (CBD), a non-psychoactive compound derived from Cannabis Sativa, has garnered increasing attention for its diverse therapeutic potential. This comprehensive review delves into the complex pharmacokinetics of CBD, including factors such as bioavailability, distribution, safety profile, and dosage recommendations, which contribute to compound’s pharmacological profile. CBD’s role inhibitor is explored, encompassing interactions with endocannabinoid system ion channels. The...
•The origins and courses of the coronary arteries can be detected on TTE.•Three "echo-signs" detect an anomalous origin circumflex artery.•A significant stenosis in left artery TTE.
Abstract Aims Interleukin‐1 (IL‐1) blockade may improve exercise capacity in patients with heart failure (HF) patients. The extent of the improvement and its persistence beyond discontinuation IL‐1 is unknown. Methods results primary objective was to determine changes cardiorespiratory fitness cardiac function on‐treatment blocker, anakinra, off‐treatment, after treatment cessation. We performed cardiopulmonary testing, Doppler echocardiography, biomarkers 73 HF, 37 (51%) females, 52 (71%)...
About one-third of patients undergoing percutaneous coronary interventions (PCIs) for flow-limiting stenosis continue to develop signs myocardial ischemia (MI) during exercise stress test [EST], despite successful revascularization. Coronary microvascular dysfunction is a likely major cause the persistence EST-induced MI in these patients.We studied 15 (14 men, age 67±5 years) fulfilling following strict inclusion criteria: (1) recent PCI (<6 months), with drug-eluting stent, artery stenoses...